Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

Home
/
update
/
details

Roche Expands Digital Pathology Platform to Enhance AI-Driven Cancer Diagnostics

NextEdge Admin

10 Sep 2024

1 min 42 sec

Roche has expanded its digital pathology open environment by integrating over 20 advanced AI algorithms from eight new collaborators, aimed at enhancing cancer research and diagnosis. This integration, powered by Roche’s navify® Digital Pathology software, provides pathologists and scientists easy access to cutting-edge AI tools, supporting precision medicine and targeted treatments.

The new collaborations include Deep Bio for prostate cancer detection, DiaDeep for breast cancer biomarkers, Lunit for lung cancer TPS analysis, Mindpeak for various cancer biomarkers, Owkin for microsatellite stability screening in colorectal cancer, Qritive for prostate cancer and metastasis analysis, Sonrai Analytics for MSI status in colorectal cancer, and Stratipath for breast cancer risk profiling.

Jill German, Head of Pathology Lab at Roche Diagnostics, highlighted the goal of transforming cancer research, diagnostics, and treatment through AI. Roche's end-to-end digital pathology solutions integrate AI-driven algorithms to deliver reliable, high-quality results, advancing personalized healthcare. As immunotherapy accelerates, Roche is moving AI tools from research to routine clinical practice, reaffirming its commitment to innovation and improved patient outcomes in cancer care.